Consequently, the infiltration of CD8+ T cells into the tumor was significantly increased in PFCR-treated mice compared to that in PF or PFC-treated mice (Fig. 5H, I), revealing that the potentiated chemotherapeutic effect of ropivacaine was achieved by enhancing T cell immunity. Here, CD8A is linked to neoplasm.